Browse RNF43

Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Nucleus envelope. Note=According to a report, may be secreted.
Domain PF13639 Ring finger domain
Function

E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signaling pathway by mediating the ubiquitination, endocytosis and subsequent degradation of Wnt receptor complex components Frizzled. Acts on both canonical and non-canonical Wnt signaling pathway. Acts as a tumor suppressor in the intestinal stem cell zone by inhibiting the Wnt signaling pathway, thereby resticting the size of the intestinal stem cell zone.

> Gene Ontology
 
Biological Process GO:0016055 Wnt signaling pathway
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0032801 receptor catabolic process
GO:0038018 Wnt receptor catabolic process
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043112 receptor metabolic process
GO:0072089 stem cell proliferation
GO:0198738 cell-cell signaling by wnt
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004842 ubiquitin-protein transferase activity
GO:0005109 frizzled binding
GO:0016874 ligase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0005635 nuclear envelope
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5340588: RNF mutants show enhanced WNT signaling and proliferation
R-HSA-4641263: Regulation of FZD by ubiquitination
R-HSA-162582: Signal Transduction
R-HSA-4791275: Signaling by WNT in cancer
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF43 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF43 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF43 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.440.00532
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4510.19
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.4520.0478
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8490.0328
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.1880.452
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.430.844
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.250.727
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8290.515
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4710.745
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.110.153
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.630.53
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.3960.0865
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF43 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.81.413.40.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF43. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF43. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF43.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF43. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF43 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF43 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF43
Namering finger protein 43
Aliases FLJ20315; DKFZp781H0392; URCC; RNF124; E3 ubiquitin-protein ligase RNF43
Chromosomal Location17q23.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF43 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.